Try a new search

Format these results:

Searched for:

in-biosketch:true

person:dieted01

Total Results:

300


Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients

Martel-Laferriere, Valerie; Bichoupan, Kian; Dieterich, Douglas T
Hepatitis C virus (HCV)-related liver disease is a major source of mortality in HIV-infected patients. Approximately one third of all patients with HIV are co-infected with HCV. Patients co-infected with HIV/HCV have shown lower rates of sustained virologic response with pegylated-interferon and weight-based ribavirin as well as more rapid progression of fibrosis than those with HCV mono-infection. Several direct-acting antiviral agents (DAAs), developed originally for HCV mono-infection, are being reevaluated for HIV/HCV co-infection. In addition, entirely new DAAs are being developed, including, interferon-free regimens with fewer side effects, allowing novel treatment opportunities for difficult-to-treat patients. In order for HCV DAAs to be successfully used in the HIV/HCV co-infected population several hurdles must be overcome, including adverse event management and drug-drug interactions. The aim of this review is to discuss the results of trials for new HCV therapies being developed for HIV/HCV co-infected patients and the impact of interferon-free regimens on treatment in the future.
PMID: 24172182
ISSN: 0192-0790
CID: 897182

Treating HCV in HIV 2013: on the cusp of change

Martel-Laferriere, Valerie; Dieterich, Douglas T
Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.
PMID: 24373079
ISSN: 1478-3223
CID: 897212

Efficacy of sofosbuvir and simeprevir-based regimens for 304 HCV treatment-experienced patients in a real-life setting; data from the TRIO network [Meeting Abstract]

Bacon, Bruce R; Dieterich, Douglas; Flamm, Steven L; Kowdley, Kris V; Lawitz, Eric; Milligan, Scott; Younossi, Zobair; Tsai, Naoky
ISI:000344483803024
ISSN: 1527-3350
CID: 2729022

Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network [Meeting Abstract]

Flamm, Steven L; Bacon, Bruce R; Dieterich, Douglas; Kowdley, Kris V; Lawitz, Eric; Milligan, Scott; Tsai, Naoky; Younossi, Zobair
ISI:000344483803032
ISSN: 1527-3350
CID: 2729032

The Urgent Unmet Need to Screen for Hepatitis B virus in African born Patients within the US, and Link them to Care [Meeting Abstract]

Vanderhoff, Aaron M; Shankar, Hari; Blanas, Demetri A; Bichoupan, Kian; Ndiaye, Daouda; Bekele, Mulusew; Carmody, Ellie; Martel-Laferriere, Valerie; Bekele, Saba; Branch, Andrea D; Dieterich, Douglas; Nichols, Kim E; Perumalswami, Ponni
ISI:000344483804221
ISSN: 1527-3350
CID: 2729162

Predicting Survival of HIV-Infected Patients with Liver Cancer - the SHILCA Score and Staging Model [Meeting Abstract]

Chen, Ting-Yi; Merchante, Nicolas; Citti, Caitlin C; Platt, Heather L; Badshah, Maaz B; Ventura-Cots, Meritxell; Merino, Esperanza; Kikuchi, Luciana; Jain, Mamta K; Rodriguez-Arrondo, Francisco; Minguez, Beatriz; Yin, Michael; Aytaman, Ayse; Tural, Cristina; Schwartz, Myron; Dieterich, Douglas; Aberg, Judith; Pineda, Juan; Marrero, Jorge A; Sherman, Morris; Hoshida, Yujin; Braeu, Norbert
ISI:000344483803370
ISSN: 1527-3350
CID: 2729122

Liver Transplantation for HIV-Infected Patients with Hepatocellular Carcinoma (HCC) [Meeting Abstract]

Platt, Heather L; Citti, Caitlin C; Minguez, Beatriz; Chen, Ting-Yi; Ventura-Cots, Meritxell; Hernandez, Maria D; Jalali, Ziba; Badshah, Maaz B; Yin, Michael; Aytaman, Ayse; Nelson, Mark; Rockstroh, Juergen K; Goetz, Matthew B; Schwartz, Myron; Dieterich, Douglas; Aberg, Judith; Hoshida, Yujin; Braeu, Norbert
ISI:000344483803368
ISSN: 1527-3350
CID: 2729112

Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population [Meeting Abstract]

Dieterich, Douglas; Bacon, Bruce R; Flamm, Steven L; Kowdley, Kris V; Milligan, Scott; Tsai, Naoky; Younossi, Zobair; Lawitz, Eric
ISI:000344483800047
ISSN: 1527-3350
CID: 2729012

HIV Viral Load Independently Predicts Survival in HIV-Infected Patients With Hepatocellular Carcinoma (HCC) [Meeting Abstract]

Citti, Caitlin C; Platt, Heather L; Badshah, Maaz B; Chen, Ting-Yi; Kikuchi, Luciana; Ventura-Cots, Meritxell; Chaudhary, Noami; Marcus, Sonja; Yin, Michael; Aytaman, Ayse; Aberg, Judith; Schwartz, Myron; Dieterich, Douglas; Hoshida, Yujin; Braeu, Norbert
ISI:000344483803438
ISSN: 1527-3350
CID: 2729132

The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus

Shankar, Hari; Bichoupan, Kian; Dieterich, Douglas T
INTRODUCTION: Boceprevir is an NS3/NS4A serine protease inhibitor that was approved for use in Hepatitis C virus (HCV) genotype 1 patients by the US Food and Drug Administration (FDA) in May 2011. The approval of this protease inhibitor marked a major paradigm shift in the treatment of HCV, as it was one of the first of many new small molecules specifically designed and approved for HCV. AREAS COVERED: In this article, the authors summarize boceprevir's pharmacokinetic and pharmacodynamic properties. In addition, they review Phase II and III trials of boceprevir as well as its clinical efficacy, dosing and safety. EXPERT OPINION: Boceprevir is a potent protease inhibitor for the treatment of genotype 1 HCV. It has a well-tolerated side-effect profile and increases the likelihood of SVR in naive and previously treated patients. The impending release of newer more efficacious direct-acting antivirals may limit the use of boceprevir for patients infected with HCV.
PMID: 24079600
ISSN: 1742-5255
CID: 897132